Nathalie Cucuat, Sara Adel Adly, Dankwart Rauscher, Joydeep Mukerji, Laurent Hamelin and Ravi Shrivastava
Objective: Wet cough is one of the most common pathologies in the world affecting nearly 12% of the world population. Being a multifactorial disease, involving initially viral infection, followed by bacterial secondary superinfection, damage to the throat mucosa, production of sticky mucus, and poor local immunity, there is currently no effective drug available. We conceived VB-Gy, an osmotically active filmogen solution, capable of cleaning the infected surface of all contaminants topically present, and of preparing a favorable ground for healing. The efficacy and safety of VB-Gy is assessed through a clinical trial, vs. saline solution as comparator product.
Methods: The study was a multi-centric, randomized, placebo-controlled, double-blind trial on patients suffering from wet cough. The study involved 39 in the test product group and 15 patients in the comparator group, each patient applying 3-4 sprays of investigational product 4-5 times per day, over a maximum period of 15 days. The effects on wet cough severity, frequency, chest discomfort, as well as on throat pain, irritation, requirement for antibiotics, and answers to Leicester cough questionnaire for quality of life, were evaluated.
Results: Although regular and frequent use of saline solution spray helped reduce wet cough symptoms noticeably, the test product induced very fast and nearly total regression of all clinical signs without any side effects, with statistically highly significant difference compared to placebo comparator and baseline data.
Conclusion: Treating wet cough requires a multi-target, cell-friendly, and safe approach to obtain not only symptomatic but also curative relief. VB-Gy is a completely new generation of nearly instant, safe, and multi-target therapeutic approach of treating various topical infections.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 